ACADIA Pharmaceuticals Inc.
ACAD
$16.12
-$0.50-3.01%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3.67% | 3.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.67% | 3.49% | |||
| Cost of Revenue | 43.38% | -9.53% | |||
| Gross Profit | -16.90% | 11.82% | |||
| SG&A Expenses | 9.87% | 1.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.92% | -3.63% | |||
| Operating Income | -84.99% | 52.92% | |||
| Income Before Tax | 315.10% | 4.37% | |||
| Income Tax Expenses | 187.09% | 59.27% | |||
| Earnings from Continuing Operations | 338.71% | -1.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 338.71% | -1.87% | |||
| EBIT | -84.99% | 52.92% | |||
| EBITDA | -75.16% | 48.79% | |||
| EPS Basic | 337.23% | -2.13% | |||
| Normalized Basic EPS | -72.95% | 44.02% | |||
| EPS Diluted | 335.16% | -1.30% | |||
| Normalized Diluted EPS | -72.97% | 44.49% | |||
| Average Basic Shares Outstanding | 0.34% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
